期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胰高糖素样多肽-1及受其体激动剂对2型糖尿病心血管病变的影响 被引量：4

下载PDF
导出
摘要 随着人民生活水平的提高,我国2型糖尿病（T2DM）的患病率逐年上升,因糖尿病并发症而死亡的人数也逐年增多,其中,心血管并发症是T2DM患者的主要死亡原因。作为治疗T2DM的新药——胰高糖素样多肽-1（GLP-1）及其受体激动剂最近备受关注。研究表明,GLP-1受体激动剂不仅能够刺激胰岛素分泌、抑制胰高糖素分泌,减少肝糖输出,改善外周组织对胰岛素的敏感性,延缓胃排空,抑制食欲及摄食,
作者 韩蕊 石志平 王涛 周亚茹
机构地区 河北医科大学第三医院河北省骨科生物力学重点实验室内分泌一科 河北医科大学第三医院心血管二科
出处 《中国临床医生杂志》 2015年第3期23-26,共4页 Chinese Journal For Clinicians
关键词 胰高糖素 受体激动剂 胰岛素分泌 心血管病变 拉鲁 外周组织 心血管并发症 氧化应激 心肌细胞 死亡原因
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献21

  • 1Russell-Jone D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue[ J 1. Mol Cell Endo- crinol,2009 (297) :137-140.
  • 2Knudsen LB, Knudsen SM, Wilken M, et al. Plasma protein binding of NN2211, a long-acting derivative of GLP-1, is important for its ef- ficacy[J]. Diabetes,2003(52) :A321-322.
  • 3Rodbard HW, Blonde L, Braithwaite SS, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitue [J]. Endocr Praet,2007 ( 13 ) : 1-68.
  • 4黄新梅,刘军.肠促胰岛素相关药物的临床作用研究进展[J].上海医药,2013,34(7):7-10. 被引量：4
  • 5张艳,李伟.利拉鲁肽对人脐静脉内皮细胞中核转录因子κB和单核细胞趋化蛋白1表达的影响[J].中国现代医学杂志,2013,23(6):29-33. 被引量：2
  • 6Liu H, Dear AE, Knucsen LB, et al. A long-acting glucagon-like pep- tide-1 analogue attenuates induction of plasminogen activator inhibi- tor type-1 and vascular adhesion molecules [ J ]. J Endocrinol, 2009 (201) :59-66.
  • 7Bunck MC,Comer A,Eliasson B, et al. One-year treatment with ex- enatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress [ J ]. Atherosclerosis, 2010,212 ( 1 ) : 223 -229.
  • 8Okerson T, Yan P, Stonehouse A, et al. Effects of exenatide on sys- tolic blood pressure in subjects with type 2 diabetes [ J ]. Am J Hy- pertens,2010(23) :334-339.
  • 9Nauck M,Frid A,Hermansen K,et al. Efficacy and safety compari- son of liraglutide, glimepiride, and placebo, all in combination with metformin,in type 2 diabetes : the LEAD ( liraglutide effect and ac- tion in diabetes ) -2 study [J]. Diabetes Care, 2009 ( 3 ) :84- 90.
  • 10Zinman B, Gerieh J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with met- formin and thiazolidinedione in patients with type 2 diabetes ( LEAD-4 Met+TZD) [J]. Diabetes Care ,2009 ( 32 ) :1224-1230.

二级参考文献41

  • 1高虹,宁光.胰高血糖素样肽1的胰腺外作用研究进展[J].国际内科学杂志,2007,34(7):408-411. 被引量：25
  • 2Raun K,Von VP,Gotfredsen CF,et al. Liraglutide,a long-acting glucagon- like peptide-1 analog,reduces body weight and food intake in obese candy-fed rats,whereas a dipeptidyl peptidase-IV inhibitor,vildagliptin, does not [J]. Diabetes, 2007,56 : 8-15.
  • 3Sarruf DA,Thaler JP,Morton GJ,et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats [J]. Diabetes,2010,59:1817-1824.
  • 4Yie J,Hecht R,Patel J,et al. FGF21 N-and C-termini play different roles in receptor interaction and activation [J]. Febs Lett,2009,583:19- 21.
  • 5Zhang X,Yeung DC,Karpisek M,et al. Serum FGF-21 levies are increased in obesity and independently associated with the metabolic syndrome in humans [J]. Diabetes,2008,57:1246-1253.
  • 6Elrick H, Stimmler L, Hlad C J, et al. Plasma insulin response to oral and intravenous glucose administration [J]. J Clin Endocrinol Metab,1964, 24(10): 1076-1082.
  • 7Hoist J J, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus [J]. Mol Cell Endocrinol, 2009, 297(1-2): 127-136.
  • 8Knop FK, Vilsboll T, Hojberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? [J]. Diabetes, 2007, 56(8): 1951-1959.
  • 9Nauck MA, Heimesaat MM, Hoist JJ. Preserved incretin activity of glucagon-like peptide 1 but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus [J]. J Clin Invest, 1993, 91(1): 301-307.
  • 10Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review [J]. Clin Ther, 2012, 34(6): 1247-1258.

共引文献8

同被引文献43

  • 1王育璠,彭永德.胰高血糖素样肽-1——2型糖尿病治疗的新策略[J].世界临床药物,2004,25(12):718-721. 被引量：4
  • 2中华医学会糖尿病学分会.中国2型糖尿病防治指南/2010年版[M].北京:北京大学医学出版社,2011:5.
  • 3Stolar M. Glycemic control and complications in type 2 diabetes mel- litus[J]. Am J Med,2010,123(3) :1-11.
  • 4Forte GI, Pi[ato G, Vaccarino I, et al. Risk profiles in type 2 diabe- tes (metabolic syndrome) : indentify vascular damages related com- plications EJ]- Curr Pharm Des, 2010, 16(7) :898-903.
  • 5Azcutia V, Abu-Taha M, Romacho T, et al. Inflammation deter- mines the proadhesive properties of high extracellular D-glucose in human endothelial cells in vitro and rat microvessels in vivo [ J ]. PLoS One, 2010, 5(4) :el0091.
  • 6Hanai K, Babazono T, Yoshida N, et al. Gender differences in the association between HDL cholesterol and the progression of diabetic kidney disease in type 2 diabetic patients [ J]. Nephrol Dial Trans- plant, 2012, 27(3) :1070-1075.
  • 7Ahr6n B. GLP-1 for type 2 diabetes [J].Exp Cell Res,2011,317(9): 1239.
  • 8Donnelly D. The structure and function of the glucagon-like peptide- 1 receptor and its ligands[J].Br J Pharmacol,2012,166( 1):27.
  • 9Purves G I, Kamishima T, Davies L M, et al. Exchange protein activated by cAMP (Epac) mediates cAMP-dependent but protein kinase A-insensitive modulation of vascular ATP-sensitive Potassium channels[J].J Physiol,2009,587(Pt 14):3639.
  • 10Furman B, Ong W K, Pyne N J. Cyclic AMP signaling in pancreatic islets[J].Adv Exp Med Biol,2010,654:281.

引证文献4

二级引证文献12

中国临床医生杂志
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部